- Founded Amporin Pharmaceuticals, a Swiss biotech company focused on developing a new class of small molecule drugs that can protect and repair cell membranes as the first potential acute oral disease-modifying treatments for multiple deadly degenerative diseases associated with protein misfolding and aggregation, starting with Parkinson’s disease and ALS.- Amporin won 3rd place in the Venture.ch Swiss national startup business plan competition, and recently won the final stage of Venture Kick.

- Established and led the Portfolio Management function as a member of the R&D Project Portfolio Management Leadership team.- Developed and implemented advanced new portfolio management systems, tools, processes, and analytical capabilities to measure and manage portfolio risk and uncertainty, value creation, R&D productivity and return on investment in real time.- Led regular portfolio reviews with R&D Leadership to evaluate and prioritize over 100 R&D projects and allocate a $1 billion R&D budget.

- Leading the evaluation and prioritization of projects and investments in data science and AI.- Applying Machine Learning and Artificial Intelligence to anonymized real world patient data.- Generating novel and unique patient-centric insights to accelerate the discovery and development of transformative new digital and non-digital therapies.- Improving the Standard of Care and real world patient outcomes with data science.

- Led development of the Integrated Portfolio Management Framework to evaluate and prioritize Novartis global drug development pipeline; ensured full adoption by influencing senior management and key stakeholders across the organization.- Led the annual and ongoing prioritization of the global drug pipeline in line with global enterprise-wide priorities for resource allocation and budget decisions at Novartis Innovation Management Board.- Optimized the risk-return profile and overall value of the global drug pipeline by delivering in-depth analysis and strategic insights to support each project tollgate and BD&L investment decision with an independent view at Novartis Innovation Management Board, Executive Committee and Board of Directors.- Developed new analytical capabilities and increased overall performance of the Portfolio Management function at least 100 fold by standardizing and automating all project and portfolio analysis.- Designed and built a new state-of-the-art, fully integrated, fully automated portfolio management system which enabled key decision makers to evaluate project and portfolio decisions, explore what-if scenarios and produce hundreds of standard charts, slides and reports without any errors in seconds, at the press of a button.- Designed and built a similar portfolio management system for non-drug projects in just 5 days, which enabled Novartis to evaluate, prioritize and manage all its digital and operational excellence projects.- Led a cross-functional initiative to develop a state-of-the-art AI system for estimating the probability of success of drug projects based on all available data; demonstrated a substantial improvement in predictive accuracy that will save up to USD 1 billion per year in avoidable trial costs, and led the full roll out across all projects.

- Took a sabbatical to reflect on the status and future of the Pharma industry; published a 400-page report with detailed analysis and new insights into Pharma R&D productivity, drug pricing and health economics.- Identified the root cause of the decline in Pharma R&D productivity and demonstrated that none of the industry’s current strategies would save it from imminent terminal decline; my findings were later published in a 2-part blog that became one of the most popular and influential articles ever in Endpoints, a top industry magazine.- Designed a fully automated closed-loop drug discovery system that could deliver viable new drug candidates for any cellular disease by accelerated molecular evolution, without any prior knowledge of the disease biology.

- Leading and building the Pharma & Life Sciences R&D advisory practice in Switzerland.- Developed the overall strategy, as well as new client relationships and business opportunities.- Led and supported two key projects which opened up a major new client account.- Led and managed a key project to identify and evaluate opportunities to improve R&D portfolio management capabilities for a global biotech company.- Played a key role in 2 major projects for a global pharma company; developed a framework to identify and evaluate potential game-changing innovations.- Helped several small biotech companies to evaluate and refine their business plans, including assessment of alternative commercial options and routes to market for a new in vitro diagnostic technology.

- Established and managed a global network of consultants to help pharma/biotech clients optimize their project portfolios and improve R&D productivity.- Developed a fully integrated portfolio management system to measure and manage the risk-return profile of both R&D projects and marketed products in real time.- Developed an automated portfolio optimization algorithm that enabled clients to maximize return on investment within defined budget and risk constraints.- Evaluated alternative lifecycle management options for a global biopharma company, enabling our client to take a critical strategic investment decision for its leading product.- Invited speaker/chair: gave talks on Risk in Pharma R&D at the 7th Annual PPM conference, BPE Pharma, etc.

- Led a key initiative to integrate and improve portfolio management and business intelligence systems, tools and processes across the organization.- Developed a powerful financial modeling tool to evaluate R&D projects and portfolios with automatic sales, P&L and cash flow forecasts, Monte Carlo simulations and sensitivity analysis for any potential combination of options, risks, events and scenarios.- Reduced overall portfolio risk by developing and evaluating options with individual project teams.

- Led a cross-functional team of 15 staff responsible for measuring and managing performance across all 10 Global Functions and Business Units, 70 countries and sites (17,000 employees).- Managed and transformed the company's Balanced Scorecard (BSC) system: improved strategic focus and alignment, consistency, transparency, employee engagement and overall business performance.- Presented quarterly results to the CEO and Board; conducted formal mid-year and annual performance reviews with each of the Global Function/BU Heads, together with the CEO and Head of HR.- Special project for the CEO: developed China R&D strategy and secured Board approval for €150 million new global R&D hub in Beijing.

- Managed and executed investments for a €1 billion nutrition and life sciences global VC fund.- Led and managed all stages of the investment process: proactive deal sourcing, screening, valuation, negotiation, due diligence, completion, ongoing portfolio management, and final sale/exit.- Led a triple M&A (buy-and-build) project to create a fully integrated private CRO ("one-stop shop") for nutraceutical and biotech drug development.

- Set up new biotech company to develop drugs for Alzheimer's disease based on my own technology and vision: developed the business plan, negotiated agreements, and raised £1.4 million VC funding.- Set up and managed the R&D pipeline and all scientific operations and collaborations.- Achieved all milestones on time and budget, strengthened core IP portfolio, in-licensed two new drug candidates, built up management team and secured £1 million further VC funding.- Awarded Young Northwest Biotechnologist of the Year 2003 by NWDA.

- Advised big pharma clients on R&D strategy, organization, project and portfolio management systems, processes, productivity and performance management.

- Invented and patented a new class of protein aggregation inhibitors as potential drug candidates for diabetes, Alzheimer’s and Parkinson’s diseases, supported by over 30 scientific papers.

- Cloned and characterized a mystery enzyme, identified its function and discovered a family of related proteins; published as first author in JBC.